The 26 most recent market catalysts affecting $ARGX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1250
Morgan Stanley's analyst Sean Laaman has maintained an 'Overweight' rating on argenx and slightly raised the price target from $1230 to $1250. This action signals continued bullish…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 85
argenx shares are trading higher after UBS upgraded its rating on the stock from Neutral to Buy and raised its price target from $960 to $1400. Also, Wells Fargo maintained its Overweight rating and raised its price target from $1350 to $1415.
This headline represents a significant positive catalyst for arGEN-X. Upgrades from 'Neutral' to 'Buy' by a major institution like UBS, coupled with substantial price target increa…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 75
UBS Upgrades argenx to Buy, Raises Price Target to $1400
UBS analyst Xian Deng upgraded argenx (ARGX) from Neutral to Buy and raised the price target from $960 to $1400. This significant upgrade from a major investment bank indicates a s…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on argenx and raised the price target from $1350 to $1415. This action signals a positive outlook from a promine…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on argenx, Raises Price Target to $1095
Truist Securities analyst Danielle Brill has updated her outlook on argenx, raising the price target from $1030 to $1095 while maintaining a 'Buy' rating. This action signals a str…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on argenx, Raises Price Target to $1100
RBC Capital's analyst Luca Issi has maintained an 'Outperform' rating on argenx (ARGX) and raised the price target from $1025 to $1100. This action signals continued confidence in …
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 85
These Analysts Boost Their Forecasts On Argenx
Argenx (ARGX) disclosed positive topline results from its Phase 3 ALKIVIA study for VYVGART Hytrulo, a treatment for autoimmune myositis. The study successfully achieved its primar…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
Citizens Maintains Market Outperform on argenx, Raises Price Target to $1200
Citizens analyst Jason N. Butler has maintained a 'Market Outperform' rating on argenx and raised the price target from $932 to $1200. This significant increase in the price target…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
Wedbush Maintains Outperform on argenx, Raises Price Target to $1150
Wedbush analyst David Nierengarten has maintained an 'Outperform' rating for argenx and raised the price target from $1050 to $1150. This action signals increased confidence from t…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on argenx, Raises Price Target to $1202
HC Wainwright & Co. analyst Douglas Tsao has maintained a 'Buy' rating on argenx (ARGX) and raised the price target from $940 to $1202. This significant increase in the price targe…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on argenx, Raises Price Target to $1215
Piper Sandler analyst Allison Bratzel has maintained an 'Overweight' rating on argenx and significantly raised the price target from $1075 to $1215. This action signals increased c…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 92
Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal
Argenx reported highly positive Phase 3 trial results for VYVGART Hytrulo in autoimmune myositis, demonstrating statistically significant and clinically meaningful improvements ove…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 92
argenx shares are trading higher after the company announced topline results from the ALKIVIA Phase 3 study met its primary endpoint.
The successful Phase 3 trial for ALKIVIA is a major catalyst for argenx, indicating strong potential for a new blockbuster drug. This positive news significantly de-risks the compa…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
Argenx's Efgartigimod Becomes First Phase 3 Therapy To Show Statistically Significant, Clinically Meaningful Improvement In IMNM, A Subtype With No Approved Treatment
Argenx's efgartigimod achieved statistically significant and clinically meaningful improvements in its Phase 3 trial for IMNM and DM patients, meeting the primary endpoint. This is…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 95
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte Biosciences
argenx has formally initiated its tender offer to acquire Forte Biosciences for $77.00 per share in cash. This is a significant corporate event, as it marks the official start of t…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 65
Guggenheim Reinstates Buy on argenx, Maintains $1185 Price Target
Guggenheim analyst Yatin Suneja has reinstated a 'Buy' rating on argenx (ARGX) and maintained a robust $1185 price target. This action signals continued confidence from a major inv…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on argenx, Raises Price Target to $1050
Wedbush analyst David Nierengarten maintained an 'Outperform' rating on argenx and raised the price target from $1000 to $1050. This action signals continued bullish sentiment from…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 95
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
Argenx is acquiring Forte Biosciences for $2.2 billion, paying $77 per share in cash. The primary driver for this acquisition is Forte's lead asset, FB102, an anti-CD122 antibody t…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 95
Argenx To Acquire Forte Biosciences For $77 Per Share Cash, Valuing Deal At ~$2.2B, Adding CD122-Targeting FB102 With Vitiligo And Celiac Data
Argenx is acquiring Forte Biosciences for approximately $2.2 billion in cash, valuing Forte at $77 per share. This transaction is a major corporate catalyst, as it significantly ex…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Oppenheimer Maintains Outperform on argenx, Raises Price Target to $1037
Oppenheimer analyst Leland Gershell has raised the price target for argenx (ARGX) from $1014 to $1037 while maintaining an 'Outperform' rating. This action signals continued bullis…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on argenx, Raises Price Target to $1025
RBC Capital's analyst Luca Issi has maintained an 'Outperform' rating for argenx and raised the price target from $945 to $1025. This action signals continued confidence in the com…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on argenx, Raises Price Target to $1185
Guggenheim analyst Yatin Suneja has maintained a 'Buy' rating on argenx and raised the price target from $1135 to $1185. This action indicates that the analyst sees continued upsid…
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 55
Citizens Maintains Market Outperform on argenx, Lowers Price Target to $932
Citizens analyst Jason Butler has updated their valuation for argenx, reducing the price target from $944 to $932. Despite this reduction, the 'Market Outperform' rating remains un…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
argenx SE shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline signifies a strong positive catalyst for arGEN-X, as better-than-expected financial results directly impact investor confidence and stock valuation. The key risk woul…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 95
argenx Q2 EPS $7.32 Beats $6.24 Estimate, Sales $1.542B Beat $1.442B Estimate
argenx's Q2 earnings per share of $7.32 significantly surpassed the $6.24 consensus estimate, representing a 95.72% increase year-over-year. Similarly, quarterly sales of $1.542 bi…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on argenx, Raises Price Target to $1182
Citigroup analyst Samantha Semenkow maintained a 'Buy' rating on argenx and raised the price target from $1152 to $1182. This action signals continued bullish sentiment from a majo…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.